Concepedia

Publication | Open Access

Albinterferon alfa‐2b dosed every two or four weeks in interferon‐naïve patients with genotype 1 chronic hepatitis C†‡

DOIFull Paper Access

80

Citations

16

References

2008

Year

Stefan Zeuzem, Eric M. Yoshida, Yves Benhamou, Stephen Pianko, Vincent G. Bain, Daniel Shouval, Robert Flisiak, Vratislav Řehák, Mircea Grigorescu, Kelly Kaita,
Hepatology

Abstract

Alb-IFN administered q2wk or q4wk may offer comparable efficacy, with an improved dosing schedule, compared with PEG-IFNalpha-2a.

References

YearCitations

Page 1